Artificial Pancreas Device System Market Report 2025

This Artificial Pancreas Device System market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The artificial pancreas device system market size has grown rapidly in recent years. It will grow from $1.81 billion in 2024 to $2.07 billion in 2025 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to rising inflow of investment, growing government initiative in clinical research, growing demand for automated systems in glycemic control, intensive R&D efforts by industry players, and increasing geriatric population.

The artificial pancreas device system market size is expected to see rapid growth in the next few years. It will grow to $3.48 billion in 2029 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to growing prevalence of diabetes, increasing prevalence of pancreatic cancer, growing occurrence of diabetes and obesity, rising demand minimally invasive (MI) drug delivery systems, and driving innovation in diabetes management technology. Major trends in the forecast period include technological innovations, increasing research and development activities, increasing product approvals, partnerships and collaborations, and increasing activities in tele consultancy for follow-up.

The growing incidence of pancreatic cancer is projected to drive the expansion of the artificial pancreas device system (APDS) market. Pancreatic cancer is a malignant tumor originating in the pancreas, which is located behind the stomach. The development of pancreatic cancer is influenced by a mix of lifestyle, genetic, medical, and environmental factors, including genetic mutations that can cause hereditary pancreatitis and result in chronic pancreatic inflammation. An artificial pancreas device system is primarily designed to assist individuals with diabetes in managing their blood sugar levels by automatically monitoring glucose and delivering the appropriate amount of insulin. For example, in March 2024, according to theCancer Australia, an Australia-based government agency, estimated that 4,506 new cases of pancreatic cancer were diagnosed in 2023, up from 3,751 cases over the previous five years. Thus, the rising prevalence of pancreatic cancer is contributing to the growth of the artificial pancreas device system market.

Key players in the artificial pancreas device system market are developing automated insulin delivery systems to improve diabetes management by automatically monitoring blood glucose levels and administering the correct amount of insulin. These systems aim to mimic the function of a healthy pancreas, alleviating the need for constant blood sugar monitoring and manual insulin injections. For instance, in May 2023, Beta Bionics, a US-based medical equipment manufacturer, received FDA 510(k) clearance for its iLet Insulin-Only Bionic Pancreas System, an automated insulin delivery device. This artificial pancreas system autonomously determines and delivers insulin doses to regulate blood glucose levels. The closed-loop system adjusts insulin delivery based on glucose levels measured by a connected continuous glucose monitor (CGM), requiring only the user’s body weight and a meal size estimate for automatic adjustments.

In September 2023, Abbott Laboratories, a US-based pharmaceutical company, acquired Bigfoot Biomedical for an undisclosed amount. This acquisition strengthens Abbott's position in diabetes care by integrating its leading Freestyle Libre continuous glucose monitoring technology with Bigfoot Biomedical’s expertise in automated insulin delivery systems. Bigfoot Biomedical, a US-based company, specializes in developing prototypes of automated insulin delivery systems, also known as artificial pancreas systems.

Major companies operating in the artificial pancreas device system market are Johnson & Johnson, Abbott Laboratories, Medtronic plc, DexCom Inc., Insulet Corporation, Tandem Diabetes Care Inc., Juvenile Diabetes Research Foundation (JDRF), Beta Bionics Inc., Glooko Inc., Bigfoot Biomedical Inc., CeQur SA, Medtrum Technologies Inc., Diabeloop SA, Beta-O2 Technologies Ltd, Pancreum Inc., TypeZero Technologies LLC, Inreda Diabetic B.V., Defymed SAS, Admetsys Corporation, DreaMed Diabetes Ltd.

North America was the largest region in the artificial pancreas device system market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial pancreas device system market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial pancreas device system market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

An Artificial Pancreas Device System (APDS) is a medical technology designed to automate blood glucose management for people with diabetes. This system combines continuous glucose monitoring (CGM) with an insulin pump and employs a sophisticated algorithm to adjust insulin delivery automatically based on real-time glucose readings. The goal of the device is to replicate the glucose-regulating function of a healthy pancreas, thus minimizing the need for manual blood glucose monitoring and insulin injections, and assisting in keeping blood glucose levels within a target range.

The artificial pancreas device system market features three main types of devices threshold suspend device systems, control-to-range systems, and control-to-target systems. Threshold suspend device systems are insulin pump technologies that automatically halt insulin delivery when blood glucose levels fall below a set threshold. The different treatment types include bi-hormonal, insulin-only, and hybrid systems, with end-users such as hospitals, medical centers, and other healthcare settings.

The artificial pancreas device system market research report is one of a series of new reports that provides artificial pancreas device system market statistics, including the artificial pancreas device system industry global market size, regional shares, competitors with artificial pancreas device system market share, detailed artificial pancreas device system market segments, market trends, and opportunities, and any further data you may need to thrive in the artificial pancreas device system industry. These artificial pancreas device system market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The artificial pancreas device system market includes revenues earned by entities by providing services such as patient monitoring, device maintenance, data management, software updates, healthcare provider consultations, and training and support for patients and healthcare professionals. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial pancreas device system market also includes sales of insulin pumps, continuous glucose monitors, control algorithms and software applications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.